Fluorine-18-fluorocyclopropylhexadecanoic acid
Alternative Names: 18F-FCPHA; 18F-fluorocyclopropylhexadecanoic acid; Cardiac PET imaging agent - FluoroPharma; CardioPET; FCPHA; Fluorocyclopropylhexadecanoic acid-F-18; trans-9-18F-Fluoro-3,4-methylenehepadecanoic acidLatest Information Update: 04 Nov 2017
At a glance
- Originator Harvard Medical School; Massachusetts General Hospital
- Developer FluoroPharma
- Class Fatty acids; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Coronary artery disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Coronary artery disease(Diagnosis) in USA (IV, Injection)
- 31 Mar 2017 FluoroPharma has patent protection for the composition and method of use of 18-F FCPHA and 18-F FTPP technologies
- 06 Jun 2016 Fluorine-18-fluorocyclopropylhexadecanoic acid licensed to Hainan Sinotau Pharmaceutical in China and Canada